Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026

About this update from Mineralys Therapeutics, Inc.

RADNOR, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced it will report its financial results from the first quarter ended March 31, 2026, after the financial markets close on Wednesday, May 6, 2026. A live webcast of the conference call may also be found on the “ News & Events ” page in the Investor Relations section of the Mineralys Therapeutics website. About Mineralys Therapeutics Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit  https://mineralystx.com . Follow Mineralys on  LinkedIn ,  Twitter  and  Bluesky . Contact: Investor Relations [email protected] Media Relations Melyssa Weible Elixir Health Public Relations Email:  [email protected]

View stock analysis, news, and events for Mineralys Therapeutics, Inc.